{"description":"SAE is delayed engraftment or failed to engraft Died before engraftment is defined as death before Absolute Neutrophil Count recovery Failure to engraft is defined as survival until at least day +42 without Absolute Neutrophil Count recovery Other AEs include acute GVHD grade III-IV and RRT grade 3-4 RRT is defined using Bearman Regimen Related Toxicity Criteria Acute GVHD grade III-IV is defined using Glucksberg criteria","eventGroups":[{"deathsNumAffected":8,"deathsNumAtRisk":20,"description":"Eligible patients are treated with busulfan IV over 2 hours on days -7 to -4, cyclophosphamide IV over 2 hours on days -3 and -2, antithymocyte globulin (ATG) IV over 10 hours on days -3 to -1 (BuCyATG) and cord blood is infused on day 0; or are treated with cyclophosphamide IV over 2 hours on days -5 and -4, antithymocyte globulin (ATG) IV over 10 hours on days -3 to -1, and undergo TBI twice a day on days -3 to -1 (CyATGTBI) and cord blood is infused on day 0","id":"EG000","otherNumAffected":5,"otherNumAtRisk":20,"seriousNumAffected":5,"seriousNumAtRisk":20,"title":"Arm 1"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Overall grade III-IV acute graft-versus-host disease","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":20,"numEvents":5}],"term":"Severe Acute graft-versus-host disease"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"DBE: Died before engraftment (did not achieve absolute neutrophil recovery) FTE: Failed to engraft (survived to at least day +42 without absolute neutrophil recovery","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":20,"numEvents":5}],"term":"DBE/FTE"}],"timeFrame":"Adverse Event, Serious Adverse Event and All Cause Mortality are from start of treatment (Day -7 or -5) through day +100 after cord blood infusion"}